Bristol Myers wins a megablockuster bet with TYK2 FDA approval — and there’s a big bonus for the label

Bristol Myers Squibb made a megablockbuster bet on deucravacitinib, the experimental TYK2 drug the company landed in the Celgene buyout, keeping it while auctioning off the rival Otezla to Amgen for $13.4 billion. Friday evening, that bet paid off in a landmark win, with Bristol Myers getting a green light…

...

Click to view original post